Ian F Hermans Selected Research

Galactosylceramides (Galactocerebrosides)

1/2022	Glycolipid-peptide conjugate vaccines elicit CD8+ T-cell responses and prevent breast cancer metastasis.
1/2021	Using agonists for iNKT cells in cancer therapy.
1/2018	A phase I vaccination study with dendritic cells loaded with NY-ESO-1 and α-galactosylceramide: induction of polyfunctional T cells in high-risk melanoma patients.
4/2015	An adjuvanted whole cell vaccine as post-remission immunotherapy for acute leukemia.
11/2014	An autologous leukemia cell vaccine prevents murine acute leukemia relapse after cytarabine treatment.
11/2014	A self-adjuvanting vaccine induces cytotoxic T lymphocytes that suppress allergy.
3/2013	Functional invariant natural killer T-cell and CD1d axis in chronic lymphocytic leukemia: implications for immunotherapy.
12/2012	Vaccination with irradiated tumor cells pulsed with an adjuvant that stimulates NKT cells is an effective treatment for glioma.
5/2012	Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ian F Hermans Research Topics

Disease

29	Neoplasms (Cancer) 01/2022 - 05/2002
4	Infections 05/2022 - 11/2017
4	Melanoma (Melanoma, Malignant) 01/2021 - 12/2003
4	Glioma (Gliomas) 01/2017 - 12/2012
3	Communicable Diseases (Infectious Diseases) 01/2017 - 05/2002
2	Malaria 05/2022 - 01/2020
2	Hypoxia (Hypoxemia) 01/2021 - 08/2006
2	Glioblastoma (Glioblastoma Multiforme) 06/2015 - 01/2015
2	Leukemia 04/2015 - 11/2014
2	Inflammation (Inflammations) 11/2014 - 08/2006
2	Experimental Melanoma 06/2009 - 12/2003
1	Meningioma (Meningiomas) 06/2022
1	Neoplasm Metastasis (Metastasis) 01/2022
1	Triple Negative Breast Neoplasms 01/2022
1	Breast Neoplasms (Breast Cancer) 01/2022
1	Atopic Dermatitis (Atopic Eczema) 10/2021
1	Prostatic Neoplasms (Prostate Cancer) 01/2021
1	Porcine Reproductive and Respiratory Syndrome (PRRS) 12/2020
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2020
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2020
1	Cytokine Release Syndrome 01/2020
1	Neurotoxicity Syndromes (Toxic Encephalopathy) 01/2020
1	Bacterial Infections (Bacterial Infection) 01/2018
1	Testicular Neoplasms (Testicular Cancer) 01/2018
1	Bacteremia 01/2018
1	Human Influenza (Influenza) 11/2017
1	Lymphoma (Lymphomas) 10/2015
1	Hypersensitivity (Allergy) 11/2014
1	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/2013
1	Necrosis 08/2006
1	Vaccinia 11/2003

Drug/Important Bio-Agent (IBA)

18	VaccinesIBA 01/2022 - 12/2004
9	Galactosylceramides (Galactocerebrosides)IBA 01/2022 - 05/2012
9	AntigensIBA 01/2022 - 01/2010
7	Peptides (Polypeptides)IBA 05/2022 - 05/2002
4	GlycolipidsIBA 01/2022 - 07/2010
4	LigandsIBA 01/2021 - 12/2004
3	CytokinesIBA 01/2022 - 03/2013
3	ProdrugsIBA 01/2022 - 11/2014
2	Immune Checkpoint InhibitorsIBA 06/2022 - 01/2017
2	Conjugate VaccinesIBA 05/2022 - 01/2022
2	Synthetic Vaccines (Recombinant Vaccines)IBA 01/2020 - 05/2002
2	Neoplasm Antigens (Tumor Antigens)IBA 10/2015 - 01/2010
2	alpha-galactosylceramideIBA 07/2010 - 06/2009
2	Proteins (Proteins, Gene)FDA Link 02/2008 - 05/2002
1	OvalbuminIBA 01/2022
1	EnzymesIBA 01/2021
1	pembrolizumabIBA 01/2021
1	5-amino-6-D-ribitylaminouracilIBA 01/2021
1	Pattern Recognition ReceptorsIBA 12/2020
1	Chimeric Antigen ReceptorsIBA 01/2020
1	RezafunginIBA 01/2020
1	Heparin-binding EGF-like Growth Factor (HB-EGF)IBA 01/2018
1	Interleukin-12 (IL 12)IBA 01/2018
1	Interleukin-12 Subunit p40IBA 01/2018
1	Protein Subunit VaccinesIBA 11/2017
1	Temozolomide (Temodar)FDA LinkGeneric 01/2015
1	InterferonsIBA 01/2015
1	Cytarabine (Cytosar-U)FDA LinkGeneric 11/2014
1	AllergensIBA 11/2014
1	fludarabineIBA 03/2013
1	Contrast MediaIBA 01/2013
1	Interleukin-4 (Interleukin 4)IBA 05/2012
1	Pharmaceutical PreparationsIBA 08/2006
1	vadimezanIBA 08/2006
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2006
1	Alkylating AgentsIBA 12/2003
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2003
1	Recombinant DNA (Recombinant DNA Research)IBA 12/2003
1	DNA (Deoxyribonucleic Acid)IBA 11/2003

Therapy/Procedure

12	Therapeutics 01/2022 - 12/2003
12	Immunotherapy 01/2021 - 12/2003
3	Drug Therapy (Chemotherapy) 06/2015 - 11/2014
2	Stem Cell Transplantation 04/2015 - 11/2014
1	Transplantation 01/2020
1	Retreatment 01/2015
1	Chemoradiotherapy 01/2015
1	Intravenous Injections 12/2012